XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

NCT05275374 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

221

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
BRAF V600 Mutation
Melanoma
Colorectal Cancer
Thyroid Cancer
Nonsmall Cell Lung Cancer

Interventions

DRUG: XP-102
DRUG: Trametinib

Sponsor

Xynomic Pharmaceuticals, Inc.